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Cardiac Uptake of Minocycline
and Mechanisms for In Vivo Cardioprotection
Diego Romero-Perez, BS, Eduardo Fricovsky, PHARMD, Katrina Go Yamasaki, BS,
Michael Griffin, PHD, Maraliz Barraza-Hidalgo, BS, Wolfgang Dillmann, MD,
Francisco Villarreal, MD, PHD
San Diego, California
Objectives: The ability of minocycline to be transported into cardiac cells, concentrate in normal and ischemic myocardium,
and act as a cardioprotector in vivo was examined. We also determined minocycline’s capacity to act as a re-
ducer of myocardial oxidative stress and matrix metalloproteinase (MMP) activity.
Background: The identification of compounds with the potential to reduce myocardial ischemic injury is of great interest. Tet-
racyclines are antibiotics with pleiotropic cytoprotective properties that accumulate in normal and diseased tis-
sues. Minocycline is highly lipophilic and has shown promise as a possible cardioprotector. However, minocy-
cline’s potential as an in vivo cardioprotector as well as the means by which this action is attained are not well
understood.
Methods: Rats were subjected to 45 min of ischemia and 48 h of reperfusion. Animals were treated 48 h before and 48 h
after thoracotomy with either vehicle or 50 mg/kg/day minocycline. Tissue samples were used for biochemical
assays and cultured cardiac cells for minocycline uptake experiments.
Results: Minocycline significantly reduced infarct size (33%), tissue MMP-9 activity, and oxidative stress. Minocycline
was concentrated 24-fold in normal (0.5 mmol/l) and 50-fold in ischemic regions (1.1 mmol/l) versus blood.
Neonatal rat cardiac fibroblasts, myocytes, and adult fibroblasts demonstrated a time- and temperature-
dependent uptake of minocycline to levels that approximate those of normal myocardium.
Conclusions: Given the high intracellular levels observed and results from the assessment of in vitro antioxidant and MMP
inhibitor capacities, it is likely that minocycline acts to limit myocardial ischemic injury via mass action
effects. (J Am Coll Cardiol 2008;52:1086–94) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.06.028r
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oetracyclines (TTCs) are broad-spectrum antibiotics and
xert antimicrobial effects by inhibiting protein synthesis.
etracyclines are classified as natural, semisynthetic, and
hemically modified (1). Two of the more common semi-
ynthetic TTCs used clinically as antibiotics are doxycycline
nd minocycline. Tetracyclines are known to chelate cal-
ium and as a consequence incorporate into teeth (which
uring dentition stains them), cartilage, and bone (2). They
lso are found at high levels in gingival tissue/saliva, and
heir accumulation has been linked with an active cellular
ptake process (3). In the 1970s, it was reported that
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Manuscript received May 6, 2008; revised manuscript received June 19, 2008,
ccepted June 20, 2008.adiolabeled TTCs accumulate in infarcted myocardium in
roportion to the degree of tissue damage (4,5). However,
he extent and means by which TTCs may accumulate in
ormal and ischemic myocardium has not been examined.
Doxycycline and minocycline possess cytoprotective
roperties (1,6–8). Effects are likely secondary to their
apacity to act as anti-inflammatory, antiapoptotic, reactive
xygen species (ROS) scavenger, and matrix metallopro-
einase (MMP) inhibitors (1,6–8). However, controversy
xists in this area, given that, for example, doxycycline is not
particularly potent MMP inhibitor, because IC50 values
re in the micromolar range (9). Thus, it is of great
mportance to determine compound tissue concentrations
ecause they would ultimately define how effective TTCs
ay be in exerting cytoprotective actions. Nonetheless, the
romise of this class of drugs in preventing and/or limiting
rgan injury is currently being explored in more than 30
ngoing clinical trials, several of which cover cardiovascular
athologies such as stroke, vascular aneurisms, coronary
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iseases such as Parkinson’s.
Of the TTCs, minocycline is unique in that it not only
as excellent bioavailability, absorption, and a long half life,
ut it is also lipophilic (7). Thus, this agent may reach very
igh tissue levels (secondary to active transport systems and
ipophilicity) and, as a consequence, have the ability to
rotect organs from ischemic injury. Indeed, reports from
tudies in which the authors used ex vivo heart systems and
ultured cells indicate that minocycline can protect myocar-
ium from ischemic injury (10). However, its potential for
n vivo cardioprotective actions has not been determined.
hus, the purpose of our study was to determine the extent
o which minocycline renders significant cardioprotection
rom ischemic injury in vivo, to examine myocardial levels
ttained, and to determine whether a cellular uptake process
s involved. For this purpose, we used a rat model of
schemia/reperfusion (I/R) injury. We also wished to estab-
ish how myocardial minocycline levels may determine the
ffectiveness of the compound in exerting cytoprotective
ctions secondary to its antioxidant and MMP inhibitor
roperties.
ethods
reatment with minocycline. Male Sprague-Dawley rats
Harlan) of 250 to 300 g were used. Two groups of rats were
enerated: control and minocycline-treated rats. Subgroups
ere used for the assessment of I/R injury (n  12 control,
 10 minocycline), hemodynamics (n  5/each), and
iochemical determinations (n  4 control, n  5 minocy-
line). A separate subgroup was generated for measurements
f tissue minocycline (n  5). Minocycline hydrochloride
as administered via intraperitoneal injection at 25 mg/kg
very 12 h, a dose within a range known to attain effective
ardioprotection ex vivo under regional ischemia (10). In
ontrol rats, water was used. Treatment began 48 h before
horacotomy and continued until 48 h of reperfusion.
rocedures were performed according to guidelines by the
merican Association for Accreditation of Laboratory An-
mal Care. The protocols were approved by the University of
alifornia, San Diego Institutional Animal Care and Use
ommittee and conform to published National Institutes of
ealth guidelines for animal research.
urgery. Animals were anesthetized by intraperitoneal in-
ection of ketamine (100 mg/kg) and xylazine (10 mg/kg),
ntubated, and positive-pressure ventilated. Hearts were
xposed through a left thoracotomy. The left anterior
escending coronary artery was occluded and released after
5 min and the suture left in place.
emodynamics. In subgroups of anesthetized animals be-
ore sacrifice, a micromanometer was inserted into the right
arotid artery to measure heart rate and carotid and left
entricular (LV) pressures.
issue sampling and staining. At 48 h of reperfusion,
eparinized/anesthetized animals were euthanized and un- cerwent cardiectomy. To delin-
ate the area at risk, the left
nterior descending coronary ar-
ery suture was retied, hearts
ere perfused with 0.4% trypan
lue using a syringe, and then
hey were sliced into 2-mm thick
ections. A single equatorial slice
as photographed and the extent
f the area at risk and infarct
reas was quantified by the use of
omputer planimetry. The re-
aining slices were used for bio-
hemical assays. The LV freewall
as separated and divided into
schemic region and border zone.
he right ventricle was used as
onischemic tissue. To distin-
uish between viable and in-
arcted myocardium, the equato-
ial slice was stained in 1% w/v
,3,5-triphenyltetrazolium chlo-
ide (i.e., TTC) in phosphate
uffer, pH 7.4, for 20 min at 37°C. Infarct area was
uantified by digital planimetry and expressed as a percent-
ge of area at risk.
elatin zymography. Tissue (50 mg) was homogenized in
0 mmol/l HEPES, pH 7.5, 150 mmol/l NaCl, 0.2 mmol/l
thylene diamine tetraacetic acid, 25% glycerol, 100 g/ml
henylmethyl sulfonylfluoride, and 0.2 kallikrein inhibitory
/ml aprotinin. Samples (10 g) were analyzed by sodium
odecyl sulfate polyacrylamide gel electrophoresis as de-
cribed (11). An internal control (human MMP-2/-9) was
oaded to normalize gels. Gelatinolytic activity was digitally
uantified.
lutathione (glutathione disulfide/glutathione [GSSG/
SH]) assay. Tissue was homogenized in buffer (154
mol/l KCl, 5 mmol/l diethylenetriaminepentaacetic acid,
nd 0.1 mol/l potassium phosphate, pH 6.8). After centrif-
gation, an aliquot was removed for protein determination.
ne volume of cold acid buffer (40 mmol/l HCl, 10 mmol/l
iethylenetriaminepentaacetic acid, 20 mmol/l ascorbic
cid, and 10% trichloroacetic acid) was added to 1 volume of
omogenate. The suspension was centrifuged and the su-
ernatant solution filtered. Reduced and oxidized glutathi-
ne (GSH) and GSSG levels, respectively, were determined
y the use of fluorophore o-phthalaldehyde (12).
ell culture. Neonatal and adult rat ventricular fibroblasts
NRVFs and ARVFs, respectively) and neonatal rat ven-
ricular myocytes (NRVMs) were prepared, as previously
escribed, with a collagenase-based method and gradient
eparations (13). We seeded NRVFs and ARVFs into
2-well cell culture plates (200,000 cells/well) and allowed
hem to proliferate to confluence (350,000 cells/well). We
eeded NRVMs into 6-well cell culture plates (500,000
Abbreviations
and Acronyms
ARVF  adult rat
ventricular fibroblast
GSH  glutathione
GSSG  glutathione
disulfide
HBSS  Hank’s balanced
salt solution
I/R  ischemia/
reperfusion
LV  left ventricular
MMP  matrix
metalloproteinase
NRVF  neonatal rat
ventricular fibroblasts
NRVM  neonatal rat
ventricular myocyte
ROS  reactive oxygen
species
TTC  tetracyclineells/well). Cells were cultured in standard serum-containing
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efore use.
inocycline transport assay in cardiac cells. Minocycline
ransport in cardiac cells was measured fluorometrically in
ach seeded well as described (3,14) with modifications. In
rief, culture plates containing cell monolayers were washed
 with Hank’s balanced salt solution (HBSS), overlaid
ith HBSS, and warmed to 37°C before the assay. Warm
BSS (0.2 ml) containing twice the desired final minocy-
line concentration (40 M) was simultaneously added to
ach well with multichannel pipettes. After incubation at
7°C and 4°C for the indicated times, the minocycline
olution was quickly removed. Each well was then rapidly
ashed 4 according to incubation temperature with either
arm (37°C) or cold (4°C) HBSS to eliminate extracellular
inocycline. Cell monolayers were lysed with 1 ml of
dH2O and then sonicated on ice 3 for 5-s bursts (resting
0 s in between to prevent overheating). The lysate was
entrifuged at 13,000g for 10 min. The supernatant was
ecovered and mixed with 1 ml of ethylene glycol containing
00 mmol/l citric acid and 200 mmol/l magnesium acetate
efore fluorescence measurement. Calibration plots were
onstructed to relate fluorescence to well minocycline con-
ent. To estimate the intracellular concentration of mino-
ycline, NRVF and ARVF cell volume was measured using
cell and particle counter (Z2 Coulter Counter, Beckman
oulter, Fullerton, California) yielding an average diameter
f 12 m. The diameter of the NRVMs was obtained from
reviously published reports (19.5 m) (15).
inocycline determination in heart tissue and plasma. Fluo-
ometric assay of minocycline in heart homogenates was
one as previously described (16) with modifications. In
rief, 150 mg of heart tissue was homogenized with a
olytron, in 2 ml of 20 mmol/l HEPES and 10 mmol/l
gCl2 solution pH 7.4. Samples were centrifuged at
3,000g for 10 min. Supernatants were recovered and
eproteinized with 0.6 ml of 1.5 mol/l trichloracetic acid.
amples were then vortexed and allowed to sit at room
emperature for 10 min. Samples were centrifuged at
3,000g for 10 min. Supernatants were recovered and
ransferred to 15-ml conical tubes. We added 0.5 ml of 0.1
ol/l HCl containing 1 mg/ml thiopropionic acid along
ith 1.0 ml of Sorense’s buffer (pH 6.0). After mixing, 0.5
l of 0.75 mol/l aluminum chloride was added, and the
ubes were shaken vigorously. After 15 min incubation at
oom temperature, fluorescence was measured (ex  384,
em  450 nm). A similar procedure was used for minocy-
line determinations in plasma. Calibration plots were
onstructed to relate fluorescence to tissue minocycline
ontent.
etermination of IC50. The inhibition of human recom-
inant MMP-7 and -9 (Calbiochem, San Diego, Califor-
ia) activity by minocycline was measured with a fluorescent
ssay kit from BIOMOL International L.P. (Plymouth
eeting, Pennsylvania). Assays contained 0.6 M MMP-7r -9 in buffer [50 mmol/l N-(2-hydroxyethyl)piperazine-=-ethanesulfonic acid, 10 mmol/l CaCl2, 0.05% Brij-35,
H 7.5] in the presence of increasing concentrations of
inocycline (0, 0.01, 0.1, 0.25, 0.5, 1, 5, 50, 100, 250, 500,
,000, 1,500, and 2,000 M). Protein was incubated with
rug for 1 h at 37°C in the dark. Cleavage reactions were
tarted by addition of the fluorescent substrate. Fluorescence
ex  335, em  405 nm) was measured at 30-s intervals
or 1 h. Cleavage rates were determined from the linear
egions of kinetic curves. We determined IC50 from graphs
f MMP activity versus log [minocycline].
he activity of MMP heart homogenates. Frozen tissue
amples were homogenized with the use of a hand-held
omogenizer on ice-cold lysis buffer (50 mmol/l Tris, pH
.4; 150 mmol/l NaCl; 5 mmol/l CaCl2; 0.2 mmol/l NaN3;
.1% Triton X-100). Homogenates were centrifuged and
upernatants isolated. We mixed 100 g of total protein
nd 20 M OmniMMP fluorogenic substrate (BIOMOL
nternational L.P.) in buffer. Given that the initial tissue
oncentration was diluted during homogenization, heart ho-
ogenates (in 100 l of buffer) derived from minocycline-
reated rats were supplemented with minocycline to reach a
nal concentration of 0.5 mmol/l (nonischemic regions) and
.1 mmol/l (ischemic regions), as determined by results
rom the minocycline tissue uptake assays described in this
tudy. Kinetic fluorescence measurements were performed
Figure 1 Reduction of Myocardial Infarct Size by Minocycline
(A) Morphometric analysis of area at risk (AAR) as a function of left ventricular
area (AAR/LV). (B) Infarct area (IA) as a function of AAR (IA/AAR) in ischemia-
reperfusion control (solid bars) (n  12) and minocycline-treated (open bars)
(n  10) hearts. Values are mean  SEM.
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ere determined from the linear regions of kinetic curves.
etermination of antioxidant activity. Antioxidant activ-
ty for minocycline and Trolox (internal control) was mea-
ured in triplicates using an in vitro Antioxidant Assay Kit
urchased from Cayman Chemical Company (Ann Arbor,
ichigan).
tatistical analysis. Results are expressed as mean SEM.
omparisons between means were analyzed, as appropriate,
y Student t test or 1-way analysis of variance followed by
onferroni t test. A value of p  0.05 was considered
tatistically significant.
esults
inocycline reduced infarct size. Body and heart weights
data not shown) were similar for both groups after I/R. In
he control group the mean area at risk (47  3.7% of LV)
as not significantly different from that in the minocycline-
reated group (41 2.7% of LV) (Fig. 1A). The infarct area
n the minocycline-treated group (30  3.5% of the area at
isk) was significantly reduced compared with that of the
ontrol group (45  4.2% of the area at risk), representing
n overall infarct reduction of 33% by minocycline (p 
Figure 2 Reduction of MMP-9 Levels in the Ischemic Region W
(A) Representative gelatin zymography of myocardial matrix metalloproteinase (MM
(n  5) hearts. (B) Bar graph derived from densitometric analysis of 92-kDa MMP
(nonischemic and ischemic) hearts regions. Values are mean  SEM. ADU  arbi.01) (Fig. 1B). The assessment of hemodynamics yielded
onsignificant differences between control versus minocycline-
reated rats in heart rate (385  25 beats/min vs. 363  35
eats/min), LV end-diastolic pressure (6.5 4 mmHg vs. 4.1
3.3 mmHg), LV systolic pressure (101 5 mmHg vs. 104
7 mm Hg), or mean arterial pressure (86  7 mm Hg vs.
6  5 mm Hg). Thus, changes in hemodynamics fail to
xplain the observed differences in infarct size.
inocycline attenuated MMP-9 up-regulation in the
schemic region. Gelatin zymography of tissue homoge-
ates from the ischemic and nonischemic regions revealed
isible bands corresponding to 92-kDa MMP-9 (Fig. 2A).
ensitometric analysis indicated that MMP-9 levels were
educed by 50% in the ischemic region of the
inocycline-treated group versus controls (p  0.01, Bon-
erroni, 6 comparisons) (Fig. 2B). We found that MMP-9
evels in the nonischemic regions remained similar between
roups. No differences in MMP-2 levels were observed in
ny group (data not shown). The 86-kDa MMP-9 band
as not quantified because it was not visible.
inocycline as an antioxidant. We explored whether
inocycline ameliorated oxidative stress in our in vivo
odel of cardiac I/R. We used GSSG/GSH as a measure of
issue oxidative stress. Ischemic tissue from minocycline-
inocycline Treatment
nd -9 levels in ischemia-reperfusion control (n  4) and minocycline-treated
ographic activity in control (nonischemic and ischemic) and minocycline-treated
ensitometric units.ith M
P)-2 a
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Cardioprotection by Minocycline September 23, 2008:1086–94reated animals displayed a significant decrease (p  0.05,
onferroni, 6 comparisons) of GSSG/GSH by 97% versus
ontrol ischemic tissue (Fig. 3). In vitro assays indicate that
inocycline bears similar antioxidant potential as the vita-
in E analog Trolox when compared at the same concen-
rations (44, 88, 135, 180, 225, and 330 M) (Fig. 4).
ccumulation of minocycline in the heart. Fluorometric
nalysis indicated that animals treated with minocycline
isplayed significant (p  0.05, Bonferroni, 4 comparisons)
ccumulation of the antibiotic in the heart by revealing
24-fold increase relative to plasma levels. Moreover,
inocycline accumulation was enhanced upon induction of
/R injury, where antibiotic concentrations reached levels
2-fold greater versus those of nonischemic regions (50-
old vs. plasma) (Fig. 5). Previous studies have shown that
uman gingival fibroblasts display an active transport mech-
nism for minocycline uptake (3,14). In cultured ARVFs
Fig. 6A), as well as in NRVF (Fig. 6B), minocycline
ccumulation also takes place in a time- and temperature-
ependent manner. At 37°C, minocycline uptake in cardiac
broblasts follows a kinetic pattern of active transport
eaching a saturation stage at 6 min, whereas at 4°C, no
ignificant accumulation occurred over time. Myocytes dis-
lay a similar minocycline uptake process as in fibroblasts
ielding a 6-fold concentration of the compound versus
xtracellular levels (Fig. 7).
inocycline as MMP inhibitor. On the basis of the IC50
alues determined, minocycline revealed an IC50 for
MP-7 (125 M) and MMP-9 (180 M) (Fig. 8). On the
asis of the results obtained regarding minocycline uptake in
eart tissue, MMP activity assays were supplemented with
.5 mmol/l for nonischemic region and 1.1 mmol/l for
Figure 3 Reduction of Tissue Oxidative
Stress With Minocycline Treatment
Tissue oxidative stress levels in control (n  4) and minocycline-treated
(n  5) animals. Decreased ratio of oxidized to reduced glutathione content
(glutathione disulfide [GSSG]/ glutathione [GSH]) was observed in ischemic
heart tissue homogenates of minocycline-treated animals. Values are mean 
SEM. RFU  relative fluorescence units.schemic region homogenates to approximate in vivo con-
entrations. Minocycline at 0.5 mmol/l in the nonischemic
issue reduced global MMP activity by 74% versus controls
ischemic and nonischemic). Minocycline at 1.1 mmol/l in
he ischemic-tissue reduced global MMP activity by 91%
ersus controls (Fig. 9). Decreases were significant (p 
.0001, Bonferroni, 6 comparisons). In addition, ischemic
issue treated with minocycline displayed a further reduction
f 66% in global MMP activity when compared with that of
onischemic tissue treated with minocycline.
iscussion
esults demonstrate the treatment of rats with minocycline
efore and after I/R yields a significant 33% reduction in
nfarct size. This is the first report for in vivo cardioprotec-
Figure 4 In Vitro Minocycline Antioxidant Potential
Using an in vitro assay kit, we found that minocycline displays antioxidant
activity similar to that of the vitamin E analog Trolox. Values are mean  SEM
of 3 experiments.
Figure 5 Accumulation of Minocycline in Plasma,
Nonischemic, and Ischemic Cardiac Tissue
Normal cardiac tissue displays a 24-fold minocycline accumulation versus
plasma, which is further enhanced by 2-fold in response to ischemia. Values
are mean  SEM (n  5).
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September 23, 2008:1086–94 Cardioprotection by Minocyclineion by minocycline. Scarabelli et al. (10) reported minocy-
line cardioprotection in cultured cardiac myocytes and
x vivo rat hearts. The cardioprotective effects were attributed
o minocycline actions on apoptotic cell pathways. We have
lso previously reported on the cardioprotective actions of
oxycycline (17,18). The ability of minocycline to limit tissue
amage in the setting of ischemia has been documented in
idney and lung (19,20). Minocycline also demonstrates neu-
oprotection in vitro and in vivo (7,21,22). Neuroprotective
echanisms include reduction of microglial activation, down-
egulation of proinflammatory/cell death mediators, and con-
rol of mitochondrial permeability (21–23). Minocycline, by
otentially acting as an MMP inhibitor, also can prevent
lood-brain barrier disruption (7,22,23).
Given this evidence, clinical studies in stroke patients have
een performed where minocycline was administered orally for
days (200 mg) with a therapeutic window of time of 6 to 24 h
fter onset of stroke (24). Patients had significantly better
utcome with minocycline versus placebo. Currently, clinical
rials are being pursued to examine for doxycycline cardiopro-
ection in coronary artery bypass patients and for amelioration
Figure 6 Minocycline Accumulation in
Neonatal and Adult Cardiac Fibroblasts
Neonatal (A) or adult (B) cells were incubated in a monolayer of 40 mol/l
minocycline in Hank’s balanced salt solution at 4°C (solid diamonds) and
37°C (open diamonds), and uptake was monitored over the indicated time
intervals. Values represent mean  SEM of 3 independent experiments.f adverse post-infarction remodeling.Investigators using radiolabeled TTC noted its capacity
o accumulate in damaged myocardium and serve to diag-
ose infarcts (5,25). Results demonstrated a correlation
etween infarct size, as determined by radiolabeled TTC,
nd serum creatine kinase. The ability of TTCs to concen-
rate in other tissues is well known (26). Dentists take
dvantage of the high concentration of doxycycline in saliva
s a means to treat periodontal (gum) disease, which
ompromises dental ligaments via MMPs. Periostat (a form
f doxycycline available from CollaGenex Pharmaceuticals,
nc., Fort Worth, Texas) is commercialized for this purpose
6). To investigate TTCs’ accumulation in gingival tissue,
ang et al. (3) examined the capacity of gingival fibroblasts
o uptake the compounds. Gingival fibroblasts transport
inocycline in a concentration- and temperature-dependent
anner. At steady state, the cellular/extracellular concen-
ration ratio was60 for minocycline. It was concluded that
ingival fibroblasts possess active transporters for TTCs that
ay explain high saliva levels of these agents. The uptake of
TCs also has been observed in neutrophils and may partly
xplain high levels observed in injured tissues (27).
We explored the capacity of minocycline to accumulate in
yocardial tissue and cells. Minocycline accumulates in myo-
ardium several-fold greater than plasma levels. Accumulation
as more pronounced in ischemic versus normal myocardium
r plasma. To identify the mechanism that may account for
yocardial accumulation, we performed experiments using
eonatal and adult rat cardiac fibroblasts and neonatal rat
ardiac myocytes. Cardiac fibroblasts possess a comparable
ptake system to that reported for gingival cells (3). Uptake
as saturable in addition to time and temperature depen-
ent. Cardiac myocytes also demonstrated uptake but with
educed magnitude. The estimation of intracellular mino-
ycline levels indicates a capacity for isolated cardiac cells to
ccumulate the compound in a magnitude compatible with
ur in vivo normal tissue results. This observation allows us
o conclude that most of the TTCs accumulated in myo-
ardium are found in physical association with cellular
tructures. However, as observed in gingiva, high intracel-
Figure 7 Minocycline Accumulation by Cardiac Myocytes
Cells were incubated in a monolayer of 40 M minocycline in Hank’s balanced
salt solution at 4°C and 37°C and uptake was monitored over the indicated
time intervals. Values represent mean  SEM of 3 independent experiments.
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Cardioprotection by Minocycline September 23, 2008:1086–94ular concentrations likely lead to high interstitial levels. We
peculate that minocycline accumulation in ischemic tissues
ay also arise from its chelation properties binding to
ivalent cations such as calcium in cells whose permeability
s compromised (28).
We previously reported a significant down-regulation of
MP-9 activity in ischemic myocardium with doxycycline
reatment 48 h after I/R (18). Minocycline treatment also
ed to a significant decrease in 92-kDa MMP-9 levels in the
schemic region. No changes were observed in the 86-kDa
orm of MMP-9 or in MMP-2 levels. We also previously
ublished the IC50 of doxycycline for MMP-7 (28 M) (9).
e performed similar in vitro determinations by using
inocycline as a means to determine the capacity of this
Figure 8 IC50 Values of Minocycline for Human Recombinant M
In vitro assays that used active MMPs show inhibition at IC50  125 M for MMP
Figure 9 Global Heart Tissue MMP Activity
Samples used were from control (n  4) and minocycline-treated (n  5) ani-
mals. Minocycline significantly inhibited global MMP activity in hearts from
nonischemic and ischemic regions versus corresponding controls. Values are
mean  SEM. Abbreviations as in Figure 2.sgent to act as an MMP inhibitor. Results yielded an IC50
or MMP-7 of 125 M and for MMP-9 of 180 M. Thus,
inocycline is a weaker MMP inhibitor versus doxycycline
n vitro, confirming previous reports (29,30).
However, because minocycline can attain millimolar con-
entrations, mass action effects may be possible on intracel-
ular or immediate extracellular MMP targets (such as
MP-2 or -9), which may activate with I/R (31). To
nvestigate this possibility, we performed global MMP
ctivity assays. Samples were homogenized in assay buffer.
ecause homogenization requires the dilution of the tissue
ample, we supplemented minocycline to the assay buffer to
enerate concentrations comparable to those derived from
n vivo measurements. At the minocycline concentrations
ested (0.5 mmol/l for nonischemic and 1.1 mmol/l for
schemic), a significant, dose-dependent reduction in MMP
ctivity was observed. A recent report shows a significant
orrelation between the degree of MMP inhibition and
rain levels of TTCs (32). Thus, it is possible that part of
he cardioprotective effects of minocycline may be derived
rom high tissue levels of the compound.
Tetracyclines also are known as antioxidants. Reductions
n ROS levels can prevent pro-MMP activation by the
ysteine switch mechanism, as observed in stroke (33).
tudies have demonstrated that the structural features of
henolic compounds and their hydroxyl radicals (as those of
TCs) confer ROS scavenger potential (28). Treatment
ith minocycline led to a significant blunting of ischemic
issue oxidative stress. These data are compatible with
revious reports in which TTCs have been shown to reduce
issue oxidative stress (34,35). Leon et al. (35) recently
eported the capacity of doxycycline to protect cardiac
yocytes from peroxynitrite-induced contractile failure in-
ependent of MMP inhibitor actions. We compared the
ntioxidant potential of minocycline versus a known ROS
and -9
IC50  180 M for MMP-9. Abbreviations as in Figure 2.MP-7
-7 andcavenger, Trolox. Results indicated that minocycline has
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September 23, 2008:1086–94 Cardioprotection by Minocyclinentioxidant potential that is comparable with Trolox. On
he basis of the antioxidant results observed and the con-
entrations measured in samples of myocardium, we can
ssume that minocycline acts as an effective ROS scavenger.
gain, this effect would result not only as a consequence of
ts unique antioxidant structural feature but also because of
ass action effects. Minocycline has also been shown to be
ytoprotective by attenuating apoptotic events/pathways (7).
t is thus possible that high concentrations of minocycline
ound in normal and ischemic tissue also allow for notable
ffects on these other targets.
tudy limitations. It is important to note the limitations
ssociated with our study. We used a pretreatment scheme
o examine the cardioprotective effects of minocycline. As
uch, the effects apply to ischemic injury and not necessarily
o reperfusion (because we did not only give the drug either
ust before or after it). Thus, the extrapolation of these
esults to the clinical scenario awaits further studies. Fur-
hermore, the use of an animal model of I/R injury has
nherent limitations when compared with patients with
oronary heart disease.
onclusions
esults from our study indicate that minocycline can act in
he in vivo setting to reduce infarct size after ischemic
njury. Minocycline cardioprotection may not only be sec-
ndary to the capacity of the compound to modulate specific
ignaling pathways but also from mass action effects on end
oints such as antioxidant and MMP inhibitor actions. The
evels of minocycline observed in tissue samples and cells
ustify a re-evaluation by investigators to consider how this
lass of drugs acts to limit tissue injury. Given their unusual
apacity to accumulate in tissues and areas of injury, one
ould even be tempted to qualify TTCs as “smart” drugs.
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